Analysts Set ALX Oncology Holdings Inc. (NASDAQ:ALXO) Price Target at $3.05

ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $3.05.

ALXO has been the topic of several research reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of ALX Oncology in a report on Friday, January 24th. UBS Group dropped their price objective on ALX Oncology from $4.00 to $2.20 and set a "buy" rating on the stock in a report on Monday, January 27th. Jefferies Financial Group lowered ALX Oncology from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $12.00 to $2.00 in a report on Thursday, December 19th. Finally, HC Wainwright dropped their price objective on ALX Oncology from $25.00 to $5.00 and set a "buy" rating on the stock in a report on Friday, January 24th.

Insider Buying and Selling

In related news, Director Rekha Hemrajani purchased 30,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were purchased at an average price of $1.55 per share, with a total value of $46,500.00. Following the completion of the acquisition, the director now directly owns 33,000 shares in the company, valued at $51,150. This represents a 1,000.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 14,443 shares of company stock valued at $23,309 over the last quarter. 33.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ALX Oncology

A number of institutional investors have recently added to or reduced their stakes in the business. Northern Trust Corp boosted its holdings in ALX Oncology by 7.3% in the 4th quarter. Northern Trust Corp now owns 343,066 shares of the company's stock valued at $573,000 after purchasing an additional 23,324 shares in the last quarter. Bank of Nova Scotia purchased a new stake in ALX Oncology in the 4th quarter valued at approximately $176,000. Bank of Montreal Can purchased a new stake in ALX Oncology in the 4th quarter valued at approximately $1,380,000. Geode Capital Management LLC boosted its holdings in ALX Oncology by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 740,106 shares of the company's stock valued at $1,236,000 after purchasing an additional 39,259 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in ALX Oncology by 476.7% in the 4th quarter. JPMorgan Chase & Co. now owns 236,046 shares of the company's stock valued at $394,000 after purchasing an additional 195,112 shares in the last quarter. Hedge funds and other institutional investors own 97.97% of the company's stock.

ALX Oncology Stock Up 1.9 %

ALX Oncology stock traded up $0.02 during midday trading on Tuesday, reaching $1.10. The company's stock had a trading volume of 314,029 shares, compared to its average volume of 1,048,731. ALX Oncology has a fifty-two week low of $0.96 and a fifty-two week high of $17.83. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07. The company has a market cap of $58.01 million, a P/E ratio of -0.37 and a beta of 0.96. The business has a 50-day simple moving average of $1.56 and a 200-day simple moving average of $1.85.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.